28 results
Thumbnail

D3.399 - An SYK Variant with Variable Spectrum of Immunodeficiency and Immune Dysregulation: Case Series

Thumbnail

D3.409 - Immunological Mechanisms in Treatment-Resistant Depression

Thumbnail

D3.413 - Basophil Activation Test Positivity and Response to Ciclosporin in Chronic Spontaneous Urticaria: A Real-World Exploratory Study

Thumbnail

D3.414 - Clinical and Laboratory Predictors of Basophil Activation Test Positivity in Chronic Spontaneous Urticaria: A Real-World Exploratory Study

Thumbnail

D3.416 - PEG-CUR Reduces Oxidative Stress and Total Methylation Induced by Cigarette Smoke in Epithelial Cells: Development of PEG-Curcumin Loaded Fast-Dissolving Microneedle Patches

Thumbnail

D3.398 - Primary Care Physicians’ Perspectives on Primary Immunodeficiency Diseases

Thumbnail

D3.401 - A mechanism for loss of biodiversity in the gut: Toxic effects and metabolic alterations of food additives on human fecal microbiome

Thumbnail

D3.402 - Evaluation of Apigenin's Anti-Inflammatory and Wound Healing Effects Using Atopic Dermatitis Cell Culture Model

Thumbnail

D3.403 - Protein Profiling of CAR-Engineered NK92-Derived Exosomes Using Western Blot

Thumbnail

D3.404 - From CVID to CTLA-4 Haploinsufficiency: The Impact of Genetic Diagnosis on Targeted Therapy

Thumbnail

D3.406 - Novel bone materials selectively modulate the human immune response to favor remodeling over acute inflammation

Thumbnail

D3.407 - Angioedema: cause or consequence?

Thumbnail

D3.408 - When Angioedema Is Not Angioedema: EBV-Associated Lymphocytic Inflammation Mimicking Hereditary Angioedema

Thumbnail

D3.415 - Galectin-10 Expression in Plasma-Derived Extracellular Vesicles of Patients with Eosinophilic Esophagitis: a Pilot Study

Thumbnail

D1.105 - Real-Life Evidence of Type 2 Immunomodulation with Benralizumab: From Steroid-Dependent to Controlled Asthma

Thumbnail

D1.106 - Dupilumab-Induced Systemic Eosinophilic Immune Activation Mimicking an EGPA-Like Prodrome: A Case Report

Thumbnail

D1.108 - Optimization of phenotyping in severe T2-bronchial asthma

Thumbnail

D1.109 - Biologics selection algorithm for severe T2-bronchial asthma targeted therapy

Thumbnail

D1.110 - Long Term Mepolizumab in Type-2 CRSwNP: Marked Polyp Reduction, Symptom Relief, and Airway Benefits in Real World Comorbid Patients

Thumbnail

D1.111 - Tezepelumab reduces in patients with severe allergic asthma and rhinoconjunctivitis not only bronchial but also nasal and conjunctival symptoms – results from an exposure chamber study